Ethical Questions About Gene Therapy for Wet Macular Degeneration
Examines ethical questions about gene therapy for wet macular degeneration in adults.
Plain-language title generated from the registry record
Registry title: Ethical Issues of Using Gene Therapy in the Treatment of AMD
Key facts
- Where
- Nantes, FranceSee the site
Where in France
- CHU Nantes - Ophthalmology DepartmentNantes, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Nantes University Hospital
- Trial code
- NCT07004361
- Record updated
- 24 June 2026
- Original description
The objective of this study is to examine the legitimacy of gene therapy use in the treatment of exudative age-related macular degeneration (AMD). This involves questioning its beneficence/non-maleficence ratio given the limited experience with this innovative technology and its irreversible effects, requiring a surgical procedure for administration. Additionally, the study explores patient autonomy in decision-making concerning complex therapeutic approaches and how patients should be supported to best uphold this autonomy.Read full original descriptionShow less
Ethical Issues of Using Gene Therapy in the Treatment of AMD (Age-related Macular Degeneration)
The objective of this study is to examine the legitimacy of gene therapy use in the treatment of exudative age-related macular degeneration (AMD). This involves questioning its beneficence/non-maleficence ratio given the limited experience with this innovative technology and its irreversible effects, requiring a surgical procedure for administration. Additionally, the study explores patient autonomy in decision-making concerning complex therapeutic approaches and how patients should be supported to best uphold this autonomy.
Inclusion: Patients with exsudative AMD, male female >18 years Patients for whom the doctor could consider gene therapy.
Exclusion: Patients with atrophic AMD (Age-related Macular Degeneration) Patients with other degenerative retinal diseases than AMD, Patients with with associated cognitive disorders.